They are the cobas EGFR Mutation Test v2 from Roche (“a quantitative PCR (qPCR)-based test for the detection of EGFR exon 19 deletions, the NP_005219.2:p.L858R substitution in metastatic NSCLC patients to identify eligibility for TKI treatment, as well as for the EGFR NP_005219.2:p.T790M resistance mutation”) [22,28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.